tiprankstipranks
Trending News
More News >
Kindstar Globalgene Technology, Inc. (HK:9960)
:9960
Hong Kong Market
Advertisement

Kindstar Globalgene Technology, Inc. (9960) AI Stock Analysis

Compare
0 Followers

Top Page

HK:9960

Kindstar Globalgene Technology, Inc.

(9960)

Rating:46Neutral
Price Target:
HK$1.50
▲(0.00% Upside)
The overall stock score is primarily influenced by financial performance challenges, including declining revenue and negative cash flows. Technical analysis provides a neutral outlook, while valuation concerns due to negative earnings further weigh down the score. The absence of earnings call data and corporate events means these factors do not influence the score.

Kindstar Globalgene Technology, Inc. (9960) vs. iShares MSCI Hong Kong ETF (EWH)

Kindstar Globalgene Technology, Inc. Business Overview & Revenue Model

Company DescriptionKindstar Global (Beijing) Technology, Inc. provides medical esoteric testing services to hospitals in China. Its services include medical research, drug trial, and translational medicine research services for physicians, medical science and technology institutions, specialty and general hospitals, and pharmaceutical companies. The company's lab platforms comprise flow cytometry, cytogenetic, medical genomics, molecular biology, hematopathology, mass spectrum, pathology, clinical immunology, microbiology, and scientific research laboratories. It provides tests in blood, tumor, and genetics; and cardiovascular, cerebrovascular, infectious, and autoimmune diseases, as well as in internal medicine, surgery, gynecology, pediatrics, and other specialties. The company was founded in 2003 and is headquartered in in Wuhan, China.
How the Company Makes MoneyKindstar Globalgene Technology, Inc. generates revenue primarily through the provision of its diagnostic testing services. The company charges healthcare providers and medical institutions for conducting specialized genetic and molecular diagnostic tests. These services are often billed on a per-test basis, allowing the company to earn income based on the volume and complexity of tests conducted. Additionally, Kindstar may engage in partnerships with hospitals, clinics, and research institutions to expand its service offerings and reach more patients. Such collaborations can lead to increased test orders and service fees. The company may also explore research collaborations or grants that support the development of new diagnostic technologies, creating potential supplementary revenue streams.

Kindstar Globalgene Technology, Inc. Financial Statement Overview

Summary
Mixed financial health with stable balance sheet but challenges in income statement and cash flow. Operational inefficiencies and negative cash flows hinder financial performance.
Income Statement
45
Neutral
The income statement reveals fluctuating revenue, with a noticeable decline of 4.1% from 2022 to 2023. Despite a positive EBITDA in 2023, the EBIT and net income margins remain negative, indicating ongoing operational inefficiencies. The gross profit margin has also decreased from 43.5% in 2022 to 45.4% in 2023, reflecting pressure on profitability. These factors contribute to a moderate income statement score.
Balance Sheet
60
Neutral
The balance sheet shows strong equity levels, with an equity ratio of approximately 73.8% in 2023. The debt-to-equity ratio is low at 0.07 in 2023, suggesting conservative leverage usage. However, the decrease in stockholders' equity from 2022 to 2023 indicates potential challenges in maintaining capital strength. Overall, the balance sheet remains relatively stable but signals caution on equity erosion.
Cash Flow
30
Negative
Cash flow analysis highlights significant challenges, with operating cash flow turning negative in 2023 and free cash flow also remaining negative. This indicates cash generation issues, compounded by zero capital expenditure reporting, which may impact future growth. The free cash flow to net income ratio is not calculable due to negative net income. These factors result in a lower cash flow score.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue927.57M967.26M1.39B930.67M891.39M
Gross Profit439.56M451.13M603.05M485.77M460.98M
EBITDA-115.25M126.38M150.72M-1.39B-909.23M
Net Income-54.59M41.29M75.46M-1.45B-974.02M
Balance Sheet
Total Assets3.77B3.67B3.73B3.19B1.58B
Cash, Cash Equivalents and Short-Term Investments1.66B2.03B2.00B2.15B956.29M
Total Debt398.36M194.29M199.86M18.19M85.39M
Total Liabilities950.51M774.23M871.62M464.15M3.41B
Stockholders Equity2.78B2.87B2.83B2.72B-1.84B
Cash Flow
Free Cash Flow-179.57M-189.65M-102.90M-220.23M46.68M
Operating Cash Flow-44.12M-14.78M21.41M68.03M73.46M
Investing Cash Flow-1.21B854.92M-1.35B-666.06M-121.96M
Financing Cash Flow144.63M-82.83M97.64M1.59B851.92M

Kindstar Globalgene Technology, Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.50
Price Trends
50DMA
1.50
Negative
100DMA
1.41
Positive
200DMA
1.30
Positive
Market Momentum
MACD
-0.01
Positive
RSI
48.03
Neutral
STOCH
56.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9960, the sentiment is Positive. The current price of 1.5 is below the 20-day moving average (MA) of 1.55, below the 50-day MA of 1.50, and above the 200-day MA of 1.30, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 48.03 is Neutral, neither overbought nor oversold. The STOCH value of 56.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:9960.

Kindstar Globalgene Technology, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
HK$675.48M8.185.33%7.92%0.47%50.46%
66
Neutral
HK$1.64B5.6420.47%4.37%-3.56%-17.45%
64
Neutral
HK$390.48M7.53-8.40%2.76%-21.31%-149.92%
54
Neutral
HK$1.69B-4.66%0.47%-0.55%45.36%
51
Neutral
$7.95B-0.38-43.43%2.22%22.30%-1.83%
48
Neutral
HK$949.39M6.5330.40%2.30%
46
Neutral
HK$1.55B130.77-3.59%1.60%-4.09%-1242.31%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:9960
Kindstar Globalgene Technology, Inc.
1.50
0.56
59.57%
HK:1518
New Century Healthcare Holding Co. Ltd.
0.80
0.02
2.56%
HK:1526
Rici Healthcare Holdings Ltd.
1.01
-0.05
-4.72%
HK:3689
Guangdong Kanghua Healthcare Co., Ltd. Class H
2.02
-0.23
-10.22%
HK:3869
Hospital Corporation of China Ltd
6.87
3.07
80.79%
HK:3886
Town Health International Medical Group Ltd.
0.26
0.00
0.00%

Kindstar Globalgene Technology, Inc. Corporate Events

Kindstar Globalgene Reports Financial Challenges Amid Market Pressures
Aug 28, 2025

Kindstar Globalgene Technology, Inc. reported a decrease in revenue and a significant net loss for the first half of 2025, attributed to external market pressures, increased operating costs, and losses from recent acquisitions. The company’s gross profit margin also declined due to these factors, impacting its financial performance and highlighting the challenges faced in maintaining profitability amidst a competitive market environment.

The most recent analyst rating on (HK:9960) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Kindstar Globalgene Technology, Inc. stock, see the HK:9960 Stock Forecast page.

Kindstar Globalgene Announces Key Leadership Changes
Aug 28, 2025

Kindstar Globalgene Technology, Inc. has announced a change in its company secretary, authorized representative, and process agent roles. Ms. Lee Mei Yi has resigned from these positions, effective August 29, 2025, and will be succeeded by Ms. Chai Haijie as the sole company secretary and Mr. Tu Zanbing as the authorized representative. Additionally, Ms. Pun Ka Ying will replace Ms. Lee as the process agent. The company expressed gratitude for Ms. Lee’s contributions during her tenure.

The most recent analyst rating on (HK:9960) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Kindstar Globalgene Technology, Inc. stock, see the HK:9960 Stock Forecast page.

Kindstar Globalgene Issues Profit Warning Amidst Revenue Decline and Acquisition Costs
Aug 22, 2025

Kindstar Globalgene Technology, Inc. has issued a profit warning, anticipating a net loss of RMB30 million to RMB35 million for the first half of 2025, compared to a net profit of RMB10.5 million in the same period of 2024. The losses are attributed to a decrease in revenue, losses from fair value changes on funds, expected credit losses related to COVID-19, and expenses from recent acquisitions. Despite these challenges, the company’s core business remains stable.

The most recent analyst rating on (HK:9960) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Kindstar Globalgene Technology, Inc. stock, see the HK:9960 Stock Forecast page.

Kindstar Globalgene Schedules Board Meeting to Review Interim Results
Aug 14, 2025

Kindstar Globalgene Technology, Inc. has announced an upcoming board meeting scheduled for August 28, 2025, to discuss and approve the company’s consolidated interim results for the first half of the year ending June 30, 2025. This meeting is significant as it will provide insights into the company’s financial health and operational performance, potentially impacting its market positioning and stakeholder confidence.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 09, 2025